Friday, February 11, 2022 12:22:48 AM
A worthy question. But not worded in a way that a CEO of a business, even a little business like Elite, could answer.
Now why is that?
Imagine for a moment Elite is working on an ANDA different in the ways that are inferred. Why would a CEO reveal answers that are likely the basis for product development? The answer can be found in another question - Why reveal the answers to questions others might be seeking? The very basis for competitive advantage is doing that which others cannot. It is quintessential VRIN when others cannot do what you can and business malpractice to give the competition the answers or even suggesting leads they are likely spending money to discover. Remember, time to market matters. As does early entry. Knowledge is a costly weapon and is not to be shared.
I trust that Elite will save their evidence for the FDA not the admiring public, and certainly not listeners to a CC who may or may not be investors and may or may not be seeking business intelligence...and that is not oxymoronic.
Once again, medical knowledge is one thing and investing in business another. But assuredly, both are very far from the knowledge needed to actually run a business effectively. For all the noise, it remains that Elite is profitable. In fact,
Now why is that?
Imagine for a moment Elite is working on an ANDA different in the ways that are inferred. Why would a CEO reveal answers that are likely the basis for product development? The answer can be found in another question - Why reveal the answers to questions others might be seeking? The very basis for competitive advantage is doing that which others cannot. It is quintessential VRIN when others cannot do what you can and business malpractice to give the competition the answers or even suggesting leads they are likely spending money to discover. Remember, time to market matters. As does early entry. Knowledge is a costly weapon and is not to be shared.
I trust that Elite will save their evidence for the FDA not the admiring public, and certainly not listeners to a CC who may or may not be investors and may or may not be seeking business intelligence...and that is not oxymoronic.
Once again, medical knowledge is one thing and investing in business another. But assuredly, both are very far from the knowledge needed to actually run a business effectively. For all the noise, it remains that Elite is profitable. In fact,
40 percent of small businesses are profitable, 30 percent break even and 30 percent are continually losing money. Here is the link... https://www.chamberofcommerce.org/small-business-statistics/
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 06/01/2026 11:00:24 AM
- Elite Pharmaceuticals Announces Filing of Abbreviated New Drug Application with the U.S. Food and Drug Administration for Generic Anticoagulant Product • Newsfile • 06/01/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
